Neurologic Imaging

Which Imaging Study Should You Order for Staging Oral, Pharyngeal, or Laryngeal Cancer?

·
Which Imaging Study Should You Order for Staging Oral, Pharyngeal, or Laryngeal Cancer?

An otolaryngologist sees a 62-year-old patient with a newly biopsied squamous cell carcinoma on the floor of the mouth. The lesion is clinically small, but the true extent of submucosal spread and potential nodal involvement is unclear. Before the case can be presented at the multidisciplinary tumor board, comprehensive staging is required to determine the optimal treatment plan—be it surgery, radiation, chemotherapy, or a combination. The immediate question for the ordering physician is which imaging study will most accurately define the local, regional, and (to some extent) distant disease burden. This article details the clinical workflow for this exact scenario, guiding the choice of imaging for initial staging of suspected or diagnosed cancers of the oral cavity, oropharynx, hypopharynx, larynx, or a cancer of unknown primary in the head and neck. According to the American College of Radiology (ACR) Appropriateness Criteria, MRI orbits face neck without and with IV contrast is a top-rated, Usually appropriate examination for this presentation.

Who Fits This Clinical Scenario?

This guidance applies specifically to the initial staging of a patient with a suspected or newly diagnosed malignancy in one of the following locations: oral cavity (e.g., tongue, floor of mouth, buccal mucosa), oropharynx (e.g., tonsil, base of tongue), hypopharynx, or larynx (e.g., vocal cords). It also covers the challenging workup of a patient presenting with a metastatic cervical lymph node, typically squamous cell carcinoma, where the primary tumor site is not apparent on physical examination—a situation known as cancer of unknown primary (CUP) of the head and neck.

It is crucial to distinguish this scenario from several related but distinct clinical presentations that follow different imaging pathways:

  • Nasopharyngeal Cancer: If the suspected primary is in the nasopharynx, or if there is a strong association with Epstein-Barr virus (EBV), the workup is different. These tumors have a unique biology and pattern of spread, often involving the skull base early. This routes to a separate ACR variant.
  • Paranasal Sinus or Nasal Cavity Cancer: Malignancies arising from these locations require specific imaging protocols to evaluate complex bony anatomy, orbital invasion, and intracranial extension.
  • Major Salivary Gland Cancer: Tumors of the parotid, submandibular, or sublingual glands have their own dedicated imaging workup focused on the gland itself, the facial nerve, and specific nodal basins.

This article is exclusively for the initial staging phase. Post-therapy assessment or surveillance imaging for treated cancers follows a separate set of recommendations.

What Diagnoses Are You Working Up in This Scenario?

In this context, a diagnosis of cancer is often already suspected or confirmed by biopsy. The primary goal of imaging is not to make the initial diagnosis but to accurately stage the disease, which determines prognosis and guides therapy. The key questions imaging aims to answer correspond to the “TNM” (Tumor, Node, Metastasis) staging system.

T-stage (Primary Tumor): The central task is to define the precise size and extent of the primary tumor. Imaging must delineate invasion into adjacent structures, such as deep muscles of the tongue, the mandible or maxilla, the laryngeal framework, or the prevertebral space. A critical finding to assess is perineural spread, where cancer tracks along nerves, which significantly worsens prognosis and alters treatment fields. MRI is particularly adept at identifying this complication.

N-stage (Regional Lymph Nodes): The second major goal is to detect metastatic disease in the cervical lymph nodes. Imaging helps determine the size, number, and location (level) of suspicious nodes. Key features of metastatic involvement include central necrosis (a cystic or non-enhancing center) and extracapsular extension (ECE), where the tumor breaks through the lymph node capsule and invades surrounding fat. ECE is a major adverse prognostic factor.

Cancer of Unknown Primary (CUP): For patients presenting with a metastatic neck node but no obvious primary lesion, imaging plays a detective role. The goal is to identify a small, hidden primary tumor, most commonly located in the palatine tonsils or the base of the tongue (the oropharynx). Modalities like PET/CT are often employed in this specific search.

Why Is MRI of the Orbits, Face, and Neck the Recommended Study for This Presentation?

For the initial T and N staging of cancers in the oral cavity, oropharynx, hypopharynx, and larynx, the ACR rates MRI orbits face neck without and with IV contrast as Usually appropriate. Its superior soft-tissue contrast resolution provides an unparalleled view of the primary tumor’s relationship with surrounding muscles, fat planes, and neurovascular structures.

The rationale for this top rating is multi-faceted:

  • Tumor Delineation: MRI excels at showing the submucosal and deep extent of tumors, which is often underestimated by clinical examination alone. It can distinguish tumor from post-biopsy inflammation or edema more effectively than other modalities.
  • Perineural Invasion: MRI is the most sensitive non-invasive test for detecting perineural tumor spread, a critical factor for treatment planning, particularly for cancers of the oral cavity. This is often seen as thickening and abnormal enhancement of cranial nerves.
  • Nodal Assessment: While both CT and MRI are effective for nodal staging, MRI can sometimes better characterize the internal architecture of lymph nodes and detect subtle signs of extracapsular extension.
  • Radiation Safety: MRI uses no ionizing radiation (0 mSv), a significant advantage, especially in younger patients or those who will require multiple follow-up scans over their lifetime.

While MRI is a top choice, two other studies are also rated Usually appropriate and serve complementary or alternative roles:

  • CT neck with IV contrast: This is an excellent and widely available alternative. It is faster than MRI, less susceptible to motion artifact, and superior for evaluating cortical bone invasion (e.g., of the mandible). However, its soft-tissue contrast is inferior to MRI. It involves a moderate radiation dose (☢☢☢ 1-10 mSv).
  • FDG-PET/CT skull base to mid-thigh: This whole-body functional imaging study is exceptionally sensitive for detecting nodal metastases and distant disease (M-stage). It is often used for staging advanced disease (Stage III/IV) or for identifying the primary site in cases of CUP. Its anatomic detail for the primary tumor is lower than dedicated CT or MRI, which is why it is often performed in addition to, not in place of, one of those studies. It carries the highest radiation dose of the appropriate options (☢☢☢☢ 10-30 mSv).

Studies like ultrasound of the neck (May be appropriate) can be useful for guiding fine-needle aspiration of suspicious nodes but are not sufficient for comprehensive primary tumor staging.

What’s Next After MRI? Downstream Workflow

The results of the initial staging MRI will directly influence the subsequent clinical pathway, which is typically determined in a multidisciplinary head and neck cancer tumor board meeting.

  • If the MRI shows early-stage, localized disease (e.g., T1-T2, N0): The patient may be a candidate for single-modality therapy, such as surgical resection or definitive radiation therapy. The detailed anatomy provided by the MRI is crucial for surgical planning.
  • If the MRI reveals locally advanced disease (e.g., large T-stage, multiple positive nodes, or extracapsular extension): The patient will likely require multimodal therapy. This often involves a combination of chemotherapy and radiation (chemoradiation), sometimes followed by surgery. An FDG-PET/CT is almost always obtained in this setting, if not already done, to screen for distant metastatic disease that would change treatment intent from curative to palliative.
  • If the MRI is for a cancer of unknown primary (CUP) and identifies a likely primary tumor: The next step is a targeted biopsy of the suspicious area during panendoscopy to confirm the site.
  • If the MRI is for CUP and does NOT identify a primary tumor: The patient may proceed to further investigation, such as panendoscopy with blind biopsies of high-yield sites (tonsils, base of tongue) and potentially a bilateral tonsillectomy, as small primaries can hide within the tonsillar crypts.

In cases where MRI findings are indeterminate, a discussion between the radiologist and the clinical team is essential. A different imaging modality, like CT for bone detail or PET/CT for metabolic activity, may be recommended to resolve the ambiguity.

Pitfalls to Avoid (and When to Get Help)

Several common pitfalls can compromise the quality and utility of initial staging imaging for head and neck cancer:

  • Inadequate Field of View: The scan must cover the entire potential path of disease, from the skull base through the thoracic inlet, to include all relevant cervical lymph node levels.
  • Patient Motion: MRI scans are lengthy, and patient motion can severely degrade image quality. Proper patient coaching and immobilization are critical. Sedation may be necessary in some cases.
  • Timing After Biopsy: Performing imaging too soon after an invasive biopsy can lead to extensive inflammation and hemorrhage, which can be mistaken for tumor, potentially over-staging the disease. A delay of 10-14 days is often preferred.
  • Ignoring MRI Contraindications: Always screen patients for absolute contraindications to MRI, such as incompatible cardiac pacemakers, cochlear implants, or certain metallic foreign bodies.

If the imaging reveals extensive disease, invasion of critical structures like the carotid artery or prevertebral fascia, or if the findings are discordant with the clinical picture, the case should be escalated for immediate review at a multidisciplinary tumor board.

Related ACR Topics and Tools

Navigating the diagnostic pathway for head and neck cancer requires careful selection of the right test for the right patient. For a broader overview of all clinical scenarios related to this topic, including post-treatment surveillance and other primary sites, please see our parent guide. The resources below can help you choose the appropriate study and understand its technical execution.

Frequently Asked Questions

Why is MRI preferred over CT when CT is also rated ‘Usually Appropriate’?

While both are excellent studies, MRI is often preferred for its superior soft-tissue contrast. This allows for better delineation of the primary tumor’s invasion into adjacent muscles (like the tongue), its relationship to nerves (perineural spread), and subtle submucosal extent. CT is a strong alternative, especially if MRI is contraindicated, if speed is critical, or if detailed evaluation of cortical bone invasion is the primary question.

What is the main role of FDG-PET/CT in the initial staging of these cancers?

FDG-PET/CT excels at whole-body staging. Its primary roles are to detect regional lymph node metastases (N-stage) and distant metastases (M-stage) in other parts of the body, such as the lungs, liver, or bones. It is particularly valuable for patients with advanced clinical stages (III/IV) and for trying to locate a primary tumor in patients with cancer of unknown primary (CUP). It is often used in conjunction with a high-resolution anatomic study like MRI or CT.

Is comprehensive imaging always necessary for a very small, early-stage (e.g., T1) oral tongue cancer?

Yes, in most cases. While a small tumor may appear localized on clinical exam, imaging is crucial for detecting occult (non-palpable) nodal metastases and for assessing the true depth of invasion, which is a key prognostic factor. An MRI can reveal deep muscle infiltration that is not apparent on the surface and can guide the extent of surgical resection.

What does ‘cancer of unknown primary’ (CUP) of the head and neck mean?

This refers to a specific clinical situation where a patient presents with a metastatic cancer, typically squamous cell carcinoma, in a cervical (neck) lymph node, but a thorough physical examination and in-office endoscopy fail to identify the original tumor site. The most common hidden primary sites are the tonsils and the base of the tongue.

Why does the recommended protocol specify ‘MRI orbits face neck’ and not just ‘MRI neck’?

This comprehensive protocol ensures the field of view is adequate to cover all potential areas of tumor origin and spread. Cancers of the oral cavity and oropharynx can extend superiorly toward the skull base, and including the face and orbits in the protocol ensures these pathways, including critical cranial nerves, are fully evaluated. It standardizes the imaging volume to prevent missing disease at the margins of a more limited scan.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 30, 2026